Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Drugmakers oppose listing prices on TV. Photo: Philippe Huguen/AFP via Getty Images
The Trump administration finalized a rule Wednesday that will require pharmaceutical companies to post the list prices of their drugs in TV commercials.
Why it matters: The drug industry may sue to block the rule, and many people are skeptical that publishing prices in ads would help patients or successfully shame drugmakers into lowering their prices. But the rule is another sign of bipartisan pressure against the industry and a step toward more transparency.
Details: The requirement would only apply to drugs that have list prices — the amount that excludes rebates and discounts — of at least $35 per month.
- Drugmakers would also have to include this line in their TV ads: "If you have health insurance that covers drugs, your cost may be different."
- Xarelto, made by Johnson & Johnson, was the first drug to disclose pricing information voluntarily back in March.
What we're watching: Whether PhRMA, other drug companies and broadcasters file a lawsuit against the rule on First Amendment grounds.
Go deeper: The Wall Street Journal published a point-counterpoint about whether disclosing drug prices was a valuable policy.